Home › Trials › NCT06031805

Evaluating the use of olaparib for advanced prostate cancer in real-world settings

A French Observational Longitudinal Multicenter Study of Adult Patients Treated in the Real-life Setting With Olaparib for the Treatment of Metastatic Castration Resistant Prostate Cancer

Observational AstraZeneca · NCT06031805

This study is testing how well the drug olaparib works and how safe it is for adult men with advanced prostate cancer in real-life situations.

Quick facts

Study typeObservational
Enrollment300 (estimated)
Ages18 Years and up
SexMale
SponsorAstraZeneca Industry-sponsored
Locations65 sites (Amiens and 64 other locations)
Trial IDNCT06031805 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess the effectiveness and safety of olaparib in adult male patients with metastatic castration-resistant prostate cancer (mCRPC) in a real-world context. It will analyze treatment sequencing, patient outcomes, and BRCA testing patterns among those who have recently started olaparib therapy. The study is prospective and multicenter, involving multiple research sites across France to gather comprehensive data on patient experiences and treatment results.

Who should consider this trial

Good fit: Ideal candidates are adult males aged 18 and older who have metastatic castration-resistant prostate cancer and have recently initiated olaparib treatment.

Not a fit: Patients who are opposed to data collection or are currently participating in another clinical trial with an investigational drug may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the real-world effectiveness of olaparib, potentially improving treatment strategies for patients with mCRPC.

How similar studies have performed: While this study focuses on real-world evidence, similar studies evaluating olaparib have shown promising results in controlled settings, suggesting potential for success in this observational approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
* Adult male patients (≥ 18 years old)
* with metastatic castration-resistant prostate cancer,
* who have initiated olaparib within at least, the last two months of study entry, at their physician's discretion or who have been enrolled in the funded early access program
* who have been informed and are not opposed to their data collection --- For Patients initiated with olaparib in fEA,

  * Still alive and who have been informed verbally and/or in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control (certified by physician);
  * who deceased and who did not object to data collection for research purpose(s) during his or her lifetime.

Exclusion criteria

* Patients opposed to the collection of their data
* Patients participating in a clinical trial with an investigational prostate cancer targeted drug within 30 days prior to Olaparib initiation

Where this trial is running

Amiens and 64 other locations

+15 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Metastatic Castration-resistant Prostate Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.